A. V. Devi et al. / Tetrahedron: Asymmetry 19 (2008) 1139–1144
1143
25
m/z = 178, 121, 91 (base peak), 77, 51, 39. ½aꢀD ¼ 156, (c 1,
(EI, M+) m/z = 249, 149, 137, 121, 109, 94, 77, 66, 41,
51, 41.
CHCl3); (lit.4c = +155 (c 1, CHCl3)).
4.5. Ethyl 2,3-dihydroxy-3-phenylpropanoate
4.9. Reverse phase HPLC analysis
1H NMR (CDCl3): d 1.2 (t, 3H, –OCH2CH3), 2.9–3.2 (br,
OH), 4.15 (q, 2H, OCH2CH3), 4.4 (d, J = 4 Hz, 1H,
CH(OH)COOEt), 5.0 (d, J = 4 Hz, PhCH(OH)), 7.3 (m,
5H, aromatic). IR (neat): mmax 3450–3350, 2957, 1736,
The disappearance of glycidate ester 1b was followed by
reverse phase HPLC. Column C-18 (250 ꢂ 5 mm), Chrom-
pack, The Netherlands. Mobile phase 70% acetonitrile–
water. Flow rate 0.7 mL/min. Detection wavelength
230 nm. Retention times: 1b 6.24 min, diol (2 + 3)
4.39 min.
1452, 1198, 1092, 703 cmꢁ1
.
4.6. Ethyl anti-(2R,3R)-2,3-isopropylinyloxy-3-phenyl pro-
anoate, 2a, and ethyl syn-( ) isopropylidinyloxy-3-phenyl
propanoate 3a
4.10. HPLC with chiral stationary phase
Enantiomeric purity was determined by HPLC analysis on
Chiralcel AD-H column (250 ꢂ 5 mm), Daicel Chemical
Industries, Japan. Mobile phase 15% isopropyl alcohol in
hexane. Flow rate 0.7 mL/min; detection wavelength
230 nm. Retention times 1a: (2S,3R) 8.1 min, (2R,3S)
8.8 min; 1b: (2R,3S) 9.52, (2S,3R) 10.74 min. 2a: (2S,3S)
15.4, (2R,3R) 16.21, (2S,3R) 18.0, (2R,3S) 19.5 min. 2b:
Peaks at 20.2, 20.9, 22.5 and 24.6 min (configurations not
assigned since the product was racemic).
To a stirred solution of 2a and 3a (420 mg, 2 mmol) and
camphor sulfonic acid (1 mg) in dichloromethane (10 mL)
was added 2,2-dimethoxypropane (1 mL, 6 mmol). After
stirring for 12 h at room temperature, aqueous sodium
bicarbonate solution (5 mL) was added. The organic layer
was separated, and the aqueous layer was extracted with
dichloromethane (2 ꢂ 20 mL). The combined organic lay-
ers were washed with brine (10 mL), dried over anhydrous
sodium sulfate, and evaporated under reduced pressure.
The residue was purified over column chromatography
[ethyl acetate/hexane, 1:100] to afford syn (24 mg, 5%)
Acknowledgments
1
and anti (390 mg, 78%). syn 3a. H NMR (CDCl3) d 1.2
(t, 3H, –OCH2CH3), 1.6 (2s, 6H, –C(CH3)2), 4.3 (m, 3H,
–OCH2CH3 + CH(O)COOEt), 5.15 (d, J = 16.7 Hz, 1H,
PhCH(O)), 7.3 (m, 5H, aromatic). anti-(2R,3R)-2a: 1H
NMR (CDCl3) d 0.75 (t, 3H, –OCH2CH3), 1.5 (s, 3H,
–C(CH3)2), 1.8 (s, 3H, –C(CH3)2); 3.45–3.8 (m, 2H,
–OCH2CH3), 4.75 (d, J = 15.0 Hz), 5.4 (d, J = 15 Hz,
1H, PhCH(O)), 7.3 (m, 5H, aromatic). IR (neat) mmax
2990, 1760, 1200 cmꢁ1. [a]D = ꢁ52 (c 1, CH2Cl2) [lit. =
ꢁ67.3 (c 1.0, CH2Cl2)]. MS (EI, M+) m/z = 210, 141,
135, 122, 105, 91, 71, 57, 43, 41.
We thank the Indo-French Center for the Promotion of
Advanced Research and CSIR, New Delhi, for financial
support.
References
1. (a) de Vries, E. J.; Janssen, D. B. Curr. Opin. Biotechnol. 2003,
14, 414–420; (b) Steinreiber, A.; Faber, K. Curr. Opin.
Biotechnol. 2001, 12, 552–558; (c) Archelas, A.; Furstoss, R.
Curr. Opin. Biotechnol. 2001, 5, 112–119; (d) Orru, R. V.;
Archelas, A.; Furstoss, R.; Faber, K. Adv. Biochem. Eng.
Biotechnol. 1999, 63, 145–167; (e) Weijers, C. A. G. M.; de
Bont, J. A. M. J. Mol. Catal. B: Enzym. 1999, 6, 199–214.
2. (a) Kim, H. S.; Lee, S. J.; Lee, E. Y. J. Mol. Catal. B: Enzym.
2006, 43, 2–8; (b) Yeates, C. A.; Smit, M. S.; Botes, A. L.;
Breytenbach, J. C.; Krieg, H. M. Enz. Microb. Technol. 2007,
4.7. (2S,3R)-Methyl (4-methoxyphenyl) glycidate
Reaction was performed (with 1.11 g, 5 mmol) as described
in Section 4.6. The reaction was complete within 12 h and
enantiomerically pure glycidate ester (466 mg, 42%) was
obtained. 1H NMR (CDCl3, 200 MHz): d 3.5 (d, 1H,
J = 2.5 Hz, C(2)H); 3.9 (s, 3H, COOCH3), 4.1 (d, 1H,
J = 2.5 Hz, C(3)H); 6.8–7.2 (dd, 4H, aromatic). IR
(KBr): 3560–3360, 2960, 2840, 1720, 1600, 1520, 1440,
1280, 1240, 1100, 1000, 840. MS (EI, M+) m/z = 208,
´
40, 221–227; (c) Kotik, M.; Brichac, J.; Kyslık, P. J. Biotech-
nol. 2005, 120, 364–375.
3. Xu, W.; Xu, J. H.; Pan, J.; Gu, Q.; Wu, X. Y. Org. Lett. 2006,
8, 1737–1740.
4. (a) Ready, J. M.; Jacobsen, E. N. J. Am. Chem. Soc. 2001, 123,
2687–2688; (b) Dodd, D. R.; Lopez, J. L.; Zepp, C. M.;
Brandt, S. U.S. Patent 6,521,445, 2003; (c) Anand, N., Kapoor
M., Taneja S. C., Koul S., Sharma R. L., Quazi G. N., U.S.
Patent 7,060,471 B2, 2006; (d) Imashiro, R.; Seki, M. J. Org.
Chem. 2004, 69, 4216–4226; (e) Zheng, G.; Yuan, Q.; Yang, L.;
Zhang, X.; Wang, J.; Sun, W. R. J. Mol. Catal. B: Enzym.
2006, 43, 133–136.
5. (a) Deng, L.; Jacobson, E. N. J. Org. Chem. 1992, 57, 4320–
4323; (b) Denis, J. N.; Greene, A. E. J. Org. Chem. 1990, 55,
1957–1959; (c) Denis, J. N.; Greene, A. E.; Serra, A. a.; Luche,
M.-J. J. Org. Chem. 1986, 51, 46–50.
151, 148, 121 (base peak), 120, 105, 91, 77, 51, 39.
25
½aꢀD ¼ þ196 (c 1, ethanol); {lit.4b = ꢁ196.2 (c 1, ethanol)
for the (2R,3S)-enantiomer}.
4.8. Methyl 2,3-dihydroxy-3-(4-methoxyphenyl) propanoate
1H NMR (CDCl3, 200 MHz): 2.57 (d, J = 6.70 Hz, 1H,
CH(OH)COOMe), 3.04 (d, J = 6.04 Hz, 1H, PhCH(OH)),
3.79 (s, 6H, COOMe + PhOMe), 4.24–4.29 (dd,
J1 = 3.02 Hz, J2 = 6.04 Hz, 1H, CH(OH)COOMe), 4.84–
4.91 (dd, J1 = 3.02 Hz, J2 = 6.04 Hz, 1H, PhCH(OH)),
6. (a) Kanerva, L. T.; Sundholam, O. J. Chem. Soc., Perkin Trans.
1 1993, 1385–1389; (b) Matasuki, K.; Sobukawa, K.; Kawai,
A.; Inoue, H.; Takeda, M. Chem. Pharm. Bull. 1993, 41, 643–
648; (c) Inoue, H.; Matasuki, K.; Oh-Ishi, T. Chem. Pharm.
6.84 (d, J = 8.30 Hz, 2H, aromatic),
d
7.25 (d,
J = 8.30 Hz, 2H, aromatic). IR (neat) mmax 3497, 3383,
3012, 2958, 2842, 1713, 1612, 1516, 1447, 1105 cmꢁ1. MS